Advertisement

Molecular Biology Reports

, Volume 41, Issue 3, pp 1807–1813 | Cite as

TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin, microsatellite instability and KRAS mutations

  • Sana AissiEmail author
  • Marie-Pierre Buisine
  • Farid Zerimech
  • Nadia Kourda
  • Amel Moussa
  • Mohamed Manai
  • Nicole Porchet
Article

Abstract

Loss of TP53 function through gene mutation is a critical event in the development and progression of colorectal cancer (CRC). Here we examined 51 primary CRC tumors from Tunisia for mutations in TP53 exons 4–9 using PCR-direct sequencing. TP53 status and mutation site/type were than correlated with nuclear protein accumulation, familial and clinicopathologic variables and data on KRAS mutations and microsatellite instability (MSI-H). The TP53 mutation analysis was possible in the tumor of 47 patients and a deleterious somatic mutation has been detected in 59.6 % of the patients (28/47) including 20 (71.4 %) missense mutations, 7 nonsense mutations (25 %) and 1 (3.6 %) frameshift mutation. 89.3 % (25/28) of the detected mutations were in exons 5–8, whereas 10.7 % (3/28) were in exon 4. Among the 27 non frameshift mutations, 89 % (24/27) were transitions and 11 % (3/27) were transversions. 64.3 % (18/27) of the altered amino acids corresponded to arginine. 74 % (20/27) were G>C to A>T transitions, and more than half (14/27) occur at hotspots codons with CpG sites. TP53 mutations correlated closely with TP53 accumulation (p = 0.0090) and inversely with MSI phenotype (p = 0.0658). A KRAS somatic mutation was identified in 25 % (7/28) of the TP53 mutated tumors. All these mutations were G>A transitions in codon 12 and all the tumors with combined alterations but one were distally located and MSS. In conclusion, frequency and types of TP53 mutations and correlations with TP53 protein accumulation, and MSI were as reported for non-Tunisian patients. However, no significant associations have been detected between TP53 mutations and clinicopathological data in Tunisian patients as previously reported.

Keywords

CRC TP53 KRAS MSI 

Abbreviations

CIN

Chromosomal instability

CRC

Colorectal cancer

FAP

Familial adenomatous polyposis

HNPCC

Hereditary nonpolyposis colorectal cancer

MLPA

Multiplex ligation dependent probe amplification

MMR

Mismatch repair

MSI

Microsatellite instability

MSI-H

MSI-high

MSS

Microsatellite stable

TP53

Tumor protein 53

Notes

Acknowledgments

This study was the result of collaboration between the Universities of Tunis-El Manar and Lille 2. S.A was supported in part by a grant from the Tunisian government. We are indebted to all family members who agreed to attend our study. We also thank Dr O. Trabelsi, Gastroenterologist in Tunis, Tunisia, for providing us with families, Dr A. Wacrenier, Department of Pathology of the CHRU of Lille, France, for her help in immunohistochemistry of MMR and TP53 proteins, and the “Plateau Commun de Biologie Moléculaire du Centre de Biologie-Pathologie” of the CHRU of Lille.

References

  1. 1.
    Ben Abdallah M (1998) Registre des cancers Nord-Tunisie 1995–1998Google Scholar
  2. 2.
    Smith G, Carey FA, Bettie J, Wilkie MJV, Lightfoot TJ, Coxhead J, Garner RC, Steele RJC, Wolf CR (2002) Mutations in APC, Kirsten-ras, and P53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99:9433–9438PubMedCrossRefGoogle Scholar
  3. 3.
    Kikuchi-Yanoshita R, Konishi M, Ito S, Seki M, Tanaka K, Maeda Y, Iino H, Fukayama M, Koike M, Mori T, Sakuraba H, Fukunari H, Iwama T, Miyaki M (1992) Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 52:3965–3971PubMedGoogle Scholar
  4. 4.
    Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N, TP53-CRC Collaborative Study Group (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518–7528PubMedCrossRefGoogle Scholar
  5. 5.
    Moussa SA, Moussa A, Kourda N, Mezlini A, Abdelli N, Zerimech F, Najjar T, Jilani SB, Porchet N, Ayed FB, Manai M, Buisine MP (2011) Lynch syndrome in Tunisia: first description of clinical features and germline mutations. International J Colorectal Disease 26:455–467CrossRefGoogle Scholar
  6. 6.
    Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R (2002) Evaluation of tumor microsatellite instability using five quasimonomrphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123:1804–1811PubMedCrossRefGoogle Scholar
  7. 7.
    Umar A, Risinger JI, Hawk ET, Barrett JC (2004) Testing guidelines for hereditary nonpolyposis colorectal cancer. Nature 4:153–158Google Scholar
  8. 8.
    Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, Robertson MA, Nichols MF, Gruenthal KM, Lynch BJ, Leppert MF, Slattery ML (2001) Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 158:1517–1524PubMedCrossRefGoogle Scholar
  9. 9.
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMedGoogle Scholar
  10. 10.
    Børresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E (1998) TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203–210PubMedGoogle Scholar
  11. 11.
    Vasen HFA, Watson P, Mecklin JP, Lynch HT, the ICG-HNPCC (1999) New criteria for the hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC (ICG-HNPCC). Gastroenterology 116:1453–1456PubMedCrossRefGoogle Scholar
  12. 12.
    Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, Saragoni L, Amadori D (2005) Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 204:484–488PubMedCrossRefGoogle Scholar
  13. 13.
    de Jong KP, Gouw AS, Peeters PM, Bulthuis M, Menkema L, Porte RJ, Slooff MJ, van Goor H, van den Berg A (2005) P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 11:4067–4073PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Sana Aissi
    • 1
    • 2
    • 3
    Email author
  • Marie-Pierre Buisine
    • 2
    • 3
    • 6
    • 7
  • Farid Zerimech
    • 6
  • Nadia Kourda
    • 5
  • Amel Moussa
    • 4
  • Mohamed Manai
    • 1
    • 3
  • Nicole Porchet
    • 2
    • 3
    • 6
    • 7
  1. 1.Laboratory of Biochemistry and Molecular BiologyScience University of TunisTunisTunisia
  2. 2.Team n°5, Centre de Recherche Jean-Pierre Aubert, INSERM U837Lille CedexFrance
  3. 3.Cancer Pole Nord-OuestLilleFrance
  4. 4.Department of GastroEnterologyCharles Nicolle Hospital of TunisTunisTunisia
  5. 5.Laboratory of AnatomopathologyCharles Nicolle Hospital of TunisTunisTunisia
  6. 6.Laboratory of Biochemistry and Molecular BiologyCHRU of LilleLilleFrance
  7. 7.H. Warembourg Medicine UniversityUniversity of Lille North of FranceLilleFrance

Personalised recommendations